bosentan 5/5 (1)

Share Button

Bosentan (Trachleer) tablets 62,5mg and 125mg

This page contains a brief description that does not cover the medication. For more information read the review in for the respective drug.


Bosentan is a tablet against pulmonary artery hypertension (pulmonary arterial hypertension / PAH) and new finger ulcers (digital ulcers). These are complications seen by systemic sclerosis (scleroderma).

The tablets work by inhibiting endothelial receptor and are thus one endothelial receptor antagonist (ERA).

Before starting treatment

Bosentan should not be used in moderate-severe hepatic impairment, for example if ALT is more than 3 times the normal limit.

Bosentan should not be combined in months Ciclosporin A (Sandimmun Neoral)

To assess efficacy (after, for example, 3 months of treatment), measurements at baseline and a desired, defined treatment goal are important.

Pregnancy and breastfeeding

Bosentan should not be used during pregnancy (women of childbearing potential must use effective contraception). Please read information about pregnancy in rheumatic diseases on a separate page.


The dosage is usually 62,5 mg tablet morning and evening for four weeks, then 125mg morning and evening.


  • Bosentan is an expensive drug, but has a lower price than Trachleer and is prescribed by a specialist and at H-prescription

Side effects

Side effects are common, and the risk must be compared with the indication for treatment. Common side effects:

  • Fluid retention in the body (edema),
  • Low blood percentage (anemia), low number of white blood cells and platelets.
  • Diarrhea
  • Itchy rash
  • Some experience nasal congestion.
  • Fainting (syncope) occurs

Checks and follow-up

Medical examinations after starting treatment should rule out signs of side effects and then whether the effect is as desired. Later the doctor continuously assess whether the treatment should continue

For more information is recommended

- Medications for rheumatic diseases

This page has had 1 visits today

Please rate this page